Sebhat; Iyassu K.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Sebhat; Iyassu K..The latest application filed is for "chromane, isochromane and dihydroisobenzofuran derivatives as mglur2-negative allosteric modulators, compositions, and their use".

Company Profile

3.22.24

Sebhat; Iyassu K. - Jersey City NJ
Sebhat; Iyassu K. - New York NY
Sebhat, Iyassu K - Hoboken NJ
Sebhat, Iyassu K. - Hoboken NJ

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2-negative allosteric modulators, compositions, and their use Grant 10,806,724 - Sebhat , et al. October 20, 2	2020-10-20
CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE App 20190247374 - Sebhat; Iyassu K. ; et al.	2019-08-15
Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2--negative allosteric modulators, compositions, and their use Grant 10,335,399 - Sebhat , et al.	2019-07-02
Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use Grant 10,072,003 - Arasappan , et al. September 11, 2	2018-09-11
CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE App 20180085358 - Sebhat; Iyassu K. ; et al.	2018-03-29
TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE App 20170305902 - Arasappan; Ashok ; et al.	2017-10-26
Cyclic benzimidazole derivatives useful as anti-diabetic agents Grant 8,895,596 - Jiang , et al. November 25, 2	2014-11-25
Prolylcarboxypeptidase inhibitors Grant 8,569,299 - Graham , et al. October 29, 2	2013-10-29
Novel Prolylcarboxypeptidase Inhibitors App 20130143859 - Graham; Thomas H. ; et al.	2013-06-06
Angiotensin II receptor antagonists Grant 8,367,711 - Ali , et al. February 5, 2	2013-02-05
Novel Cyclic Benzimidazole Derivatives Useful Anti-diabetic Agents App 20120309736 - Jiang; Jinlong ; et al.	2012-12-06
Substituted imidazoles as bombesin receptor subtype-3 modulators Grant 8,318,767 - Chen , et al. November 27, 2	2012-11-27
Angiotensin Ii Receptor Antagonists App 20120238608 - Ali; Amjad ; et al.	2012-09-20
Angiotensin II receptor antagonists Grant 8,207,208 - Ali , et al. June 26, 2	2012-06-26
Substituted imidazole as bombesin receptor subtype-3 modulators Grant 8,193,228 - Chen , et al. June 5, 2	2012-06-05
Substituted imidazoles as bombesin receptor subtype-3 modulators Grant 8,183,275 - Dobbelaar , et al. May 22, 2	2012-05-22
Substituted Imidazoles As Bombesin Receptor Subtype-3 Modulators App 20120088788 - Chen; David ; et al.	2012-04-12
Cicletanine derivatives Grant 8,119,806 - Ali , et al. February 21, 2	2012-02-21
Substituted imidazoles as bombesin receptor subtype-3 modulators Grant 8,106,070 - Chen , et al. January 31, 2	2012-01-31
Angiotensin Ii Receptor Antagonists App 20110065765 - Ali; Amjad ; et al.	2011-03-17
Angiotensin Ii Receptor Blocker Derivatives App 20110052674 - Almirante; Nicoletta ; et al.	2011-03-03
Angiotensin II receptor antagonists Grant 7,880,014 - Sebhat , et al. February 1, 2	2011-02-01
Angiotensin II receptor antagonists Grant 7,834,042 - Sebhat , et al. November 16, 2	2010-11-16
Substituted imidazoles as bombesin receptor subtype-3 modulators App 20100204236 - Dobbelaar; Peter H. ; et al.	2010-08-12
Angiotensin Ii Receptor Antagonists App 20100152259 - Sebhat; Iyassu K. ; et al.	2010-06-17
Diuretics App 20100029678 - ALI; Amjad ; et al.	2010-02-04
Substituted inmidazoles as bombesin receptor subtype-3 modulators App 20100022598 - Chen; David ; et al.	2010-01-28
Substituted imidazoles as bombesin receptor subtype-3 modulators App 20100004280 - Chen; David ; et al.	2010-01-07
Angiotensin II receptor antagonists App 20080194660 - Sebhat; Iyassu K. ; et al.	2008-08-14
Acylated Piperidine Derivatives as Melanocortin 4-Receptor Agonists App 20080051430 - Barakat; Khaled J. ; et al.	2008-02-28
Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists Grant 7,329,673 - Guo , et al. February 12, 2	2008-02-12
Acylated piperazine derivatives as melanocortin-4 receptor agonists Grant 7,160,886 - Bakshi , et al. January 9, 2	2007-01-09
Bridged piperidine derivatives as melanocortin receptor agonists Grant 7,115,628 - Ye , et al. October 3, 2	2006-10-03
Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists App 20060183904 - Guo; Liangqin ; et al.	2006-08-17
Acylated piperidine derivatives as melanocortin-4 receptor agonists Grant 7,015,235 - Goulet , et al. March 21, 2	2006-03-21
Acylated piperidine derivatives as melanocortin-4 receptor agonists App 20060035935 - Goulet; Mark T. ; et al.	2006-02-16
Acylated piperazine derivatives as melanocortin-4 receptor agonists App 20040204398 - Bakshi, Raman K. ; et al.	2004-10-14
Bridged piperidine derivatives as melanocortin receptor agonists App 20040180923 - Ye, Zhixiong ; et al.	2004-09-16
Substituted piperidines as melanocortin receptor agonists Grant 6,767,915 - Bakshi , et al. July 27, 2	2004-07-27
Acylated piperidine derivatives as melanocortin-4 receptor agonists App 20040097546 - Goulet, Mark T. ; et al.	2004-05-20
Substituted Piperidines As Melanocortin Receptor Agonists App 20030236262 - Bakshi, Raman K ; et al.	2003-12-25
Substituted piperidines as melanocortin receptor agonists App 20020019523 - Palucki, Brenda L. ; et al.	2002-02-14

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.